<DOC>
	<DOCNO>NCT01752907</DOCNO>
	<brief_summary>The purpose study determine patient education affect patient report bone pain breast cancer patient receive chemotherapy pegfilgrastim .</brief_summary>
	<brief_title>Effect Patient Education Reported Bone Pain Breast Cancer Patients Receiving Chemotherapy Pegfilgrastim</brief_title>
	<detailed_description>In study , effect patient education report bone pain breast cancer patient receive adjuvant neoadjuvant chemotherapy pegfilgrastim investigate . Each patient receive adjuvant neoadjuvant chemotherapy pegfilgrastim prophylaxis , begin first cycle continue throughout study period . The study period study first 4 cycle chemotherapy . participant plan receive regimen &gt; 4 cycle , data collect first 4 cycle . The choice chemotherapy regimen ( agent , dose , schedule ) discretion treat physician . Commercially available pegfilgrastim administer accord US Prescribing Information consider background therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Mastodynia</mesh_term>
	<criteria>Inclusion Criteria Age 18 year Eastern cooperative oncology group ( ECOG ) performance status 02 Female newly diagnose , previously treat chemotherapy , stage IIII breast cancer Planning receive least 4 cycle adjuvant neoadjuvant chemotherapy Medically eligible safely receive adjuvant neoadjuvant chemotherapy pegfilgrastim determine investigator Planning receive prophylaxis pegfilgrastim start first cycle continue throughout chemotherapy cycle study period Has provide inform consent Able understand content DVD material , investigator 's opinion Able read understand English Exclusion Criteria Planning receive weekly chemotherapy Chronic use oral nonsteroidal antiinflammatory drug ( NSAIDs ) oral antihistamine follow exception : Chronic oral aspirin use cardiovascularrelated indication Ongoing chronic pain , painful condition require treatment ( include immediate postoperative treatment surgical proceduralassociated pain ) determine investigator Chronic oral steroid use . Premedication related administration taxanes , use antiemetic allow , per usual clinical practice . Prior chemotherapy treatment cancer within 5 year current breast cancer diagnosis Prior use granulocytecolony stimulate factor ( GCSF ) Currently enrol , less 30 day since end , another clinical trial include language direct GCSF ( filgrastim , pegfilgrastim , ) granulocytemacrophage colony stimulate factor ( GMCSF ) ( sargramostim ) use Currently enrol , less 30 day since end , another interventional clinical trial include blind treatment blind treatment arm ( whether subject randomize blinded arm ) Currently enrol , less 30 day since end , another interventional clinical trial include use agent currently consider standard therapy adjuvant neoadjuvant treatment stage IIII breast cancer base National Comprehensive Cancer Network ( NCCN ) Clinical Practice Guidelines Oncology Breast Cancer Currently enrol , less 30 day since end , pain intervention study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
	<keyword>Bone Pain</keyword>
	<keyword>Education</keyword>
</DOC>